Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Non Operating Income (2022 - 2025)

Taysha Gene Therapies' Non Operating Income history spans 4 years, with the latest figure at $1.3 million for Q3 2025.

  • For Q3 2025, Non Operating Income rose 32.14% year-over-year to $1.3 million; the TTM value through Sep 2025 reached -$70000.0, down 100.07%, while the annual FY2024 figure was -$110000.0, 134.04% down from the prior year.
  • Non Operating Income for Q3 2025 was $1.3 million at Taysha Gene Therapies, up from -$129000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $103.1 million in Q4 2023 and bottomed at -$100.8 million in Q3 2023.
  • The 4-year median for Non Operating Income is -$108000.0 (2025), against an average of -$96866.7.
  • The largest YoY upside for Non Operating Income was 2999.21% in 2023 against a maximum downside of 10083600.0% in 2023.
  • A 4-year view of Non Operating Income shows it stood at -$3.6 million in 2022, then soared by 2999.21% to $103.1 million in 2023, then plummeted by 101.09% to -$1.1 million in 2024, then skyrocketed by 214.86% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Non Operating Income are $1.3 million (Q3 2025), -$129000.0 (Q2 2025), and -$108000.0 (Q1 2025).